The **SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC)** is the world’s leading member-driven organization specifically dedicated to professionals working in the field of cancer immunology and immunotherapy. A 501(c)(3) non-profit organization, SITC was established in 1984 to exchange, encourage and promote information about the promise of immunotherapy for patients with cancer.

Since our inception three decades ago, SITC has experienced tremendous growth in terms of membership, scope of our scientific initiatives, educational programs, and collaborative outreach activities. SITC strives to be a unifying force and the collective voice of the entire cancer immunotherapy field.

**MISSION STATEMENT**

It is the mission of the Society for Immunotherapy of Cancer to improve cancer patient outcomes by advancing the science, development and application of cancer immunology and immunotherapy through our core values of interaction/integration, innovation, translation and leadership in the field.

**VISION**

SITC aims to make cancer immunotherapy a standard of care and the word “CURE” a reality for cancer patients everywhere.
OUR CONSTITUENCY OF NEARLY 1,600 ACADEMIC, GOVERNMENT, INDUSTRY, CLINICAL AND BASIC SCIENTISTS AND PRACTITIONERS FROM AROUND THE WORLD SPANS 17 MEDICAL SPECIALTIES ENGAGED IN RESEARCH AND TREATMENT OF AT LEAST A DOZEN TYPES OF CANCER.

2016 has been a record-setting year, confirming SITC as the leader in the cancer immunotherapy field. Using the 2016-2018 Strategic Plan as the framework, SITC has made incredible strides to help position cancer immunotherapy as a viable treatment modality in the fight against cancer.
CULTIVATE MEANINGFUL RELATIONSHIPS

SITC is committed to increasing interactions with government agencies, as well as, parallel and peripheral organizations from around the globe to make the goal of a cure for cancer a reality.
SITC HAS CULTIVATED MEANINGFUL RELATIONSHIPS WITH THESE ORGANIZATIONS:

- Food and Drug Administration
- Stand Up to Cancer
- American Society of Clinical Oncology
- Cancer Research Institute
- National Cancer Institute/National Institutes of Health
- Foundation for the Accreditation of Cellular Therapy of CAR-T Cell Transfer Task Force
- National Coalition for Cancer Research
- American Society of Clinical Oncology
- Cancer Immunotherapy Trials Network
- American Cancer Society
- Research!America
- Association of Community Cancer Centers
- Commission on Cancer
- American Association for Cancer Research
- Friends of Cancer Research
- International Society for Cellular Therapy
SITC continues to provide the best live and online education, scientific exchange and networking opportunities to enrich the cancer immunotherapy field.

Serve as the leading resource.
New in 2016, the SITC Annual Meeting featured a nurse/pharmacist track, helping to expand SITC’s purview as the premier destination for scientific exchange, education and networking in the cancer immunotherapy field for all individuals involved in the cancer patient care.

SITC’s Advances in Cancer Immunotherapy™ program is successfully educating community clinicians, nurses and pharmacists on integrating immunotherapy into clinical practice, with an astounding 99% of survey respondents from this regional program series indicating they would recommend the program to others.

2016 marks the first year SITC offered CPE for pharmacists and reached a record number of pharmacists this year:

SITC is on pace to reach over 4,700 attendees through SITC-led educational programs over the past year — an 18% increase over the previous year.

SITC entered into its third year of a strategic partnership with Medscape Oncology offering 56 free online CME-certified educational activities with experts in the field of immunotherapy to over 100,000 learners.

Patient Resource Guide publications have been expanded to include a melanoma specific guide for patients, in both English and Spanish, and for healthcare professionals. The guide is available to 20,000 patients, 5,000 Spanish speaking patients and 5,000 medical professionals.

SITC’s cancer immunotherapy guidelines were expanded to include genitourinary malignancies (kidney, bladder, and prostate cancer), hematologic malignancies, and lung cancer.

SITC’s Annual Meeting & Associated Programs continues record growth as evidenced by a projected 33% increase in attendance from 2015 to 2016 and a 64% increase in abstract submissions from the 2013-2014 two-year period to the 2015-2016 two-year period.
THROUGH MEANINGFUL ENGAGEMENT WITH STAKEHOLDERS, SITC ACTS AS THE MAIN HUB OF INFORMATION AND PROVIDES OPPORTUNITIES FOR INTERACTION AMONGST KEY LEADERS IN THE FIELD.

CREATE A NETWORK OF STAKEHOLDERS

Membership Profile

- Regular Member: 71%
- Scientist in Training: 17%
- Affiliate: 6%
- Emeritus: 1%
- New Categories: 5%

Membership Totals

- 2012: 756
- 2013: 791
- 2014: 896
- 2015: 1,282
- 2016: 1,350
The Advances in Cancer Immunotherapy™ online component was jointly provided by Postgraduate Institute for Medicine and SITC.

The *Journal for ImmunoTherapy of Cancer* is now indexed in five major databases increasing visibility and opportunities, including PubMed, PubMed Central, Directory of Open Access Journals, Thomas Reuters’ Emerging Sources Citation Index and Elsevier’s Scopus.

The thought leader video, *SITC – Leading the Cancer Immunotherapy Evolution*, detailing its role in the cancer immunotherapy evolution, launched on YouTube.

SITC held its first-ever Virtual Summit via Twitter to highlight the Cancer Moonshot Initiative. This Virtual Summit was promoted to our national network of 25,000 immunotherapy professionals and stakeholders to expand beyond the SITC constituency encouraging others to think about cancer immunotherapy.

Through enhanced member benefits, cultivation of key constituency groups and expansion of membership to the entire cancer care team, the society has more than doubled its membership base in the last three years.

SITC expanded membership to include: Nurses, Nurse Practitioners, Physician Assistants, Allied Health Professionals, Patients and Patient Advocates. These new membership categories now account for 5% of the total SITC membership.

Nearly 500 individual volunteers have helped shape discussions that guide progress in the field.
ADVANCE THE SCIENCE
GLOBALLY

SITC UTILIZES GLOBAL PARTNERSHIPS, BRIDGES GEOGRAPHICAL DISTANCES THROUGH TECHNOLOGY AND DEVELOPS TARGETED EDUCATION IN AN EFFORT TO ADVANCE THE SCIENCE AND APPLICATION OF CANCER IMMUNOTHERAPY WORLDWIDE.
SITC has reached nearly 2,000 people internationally through collaborative educational programs, including two new countries – Egypt and Hungary.

SITC 2015 increased its international attendance by nearly 20%, showing that SITC is a respected and global leader in the field. *Journal for ImmunoTherapy of Cancer* editors represent increased international diversity and variety of specialties within the field of tumor immunology and cancer immunotherapy.

International authorship in the *Journal for ImmunoTherapy of Cancer* is on the rise.

The Global Immunoscore Validation Project led by SITC, united medical centers from around the world in an effort to validate the prognostic value of immunoscore in colon cancer patients. Initial findings were presented at the American Society of Clinical Oncology annual meeting with an update provided at SITC 2016.
SITC CHALLENGES THE STATUS QUO AND SEEKS OUT INNOVATIVE RESEARCH THAT DRIVES THE FIELD INTO THE FUTURE.

SEEK THE BEST
RESEARCH

SITC Forward Fund reached its GOAL of raising over $1 MILLION in funding over a 4 year period. To date, the fund has raised $1.2 million.

In 2016, SITC granted a record-setting $692,000 in awards through the Forward Fund—350% giving increase since 2015.
The number of citations of the *Journal for ImmunoTherapy of Cancer* is 20% ahead of 2015 year-end citations and continues to grow.

Four SITC members were named to Vice President Joe Biden’s Cancer Moonshot Blue Ribbon Panel.

2016 was a record-setting year with 7 SITC-Named Postdoctoral Cancer Immunotherapy Fellowship Awards totaling almost $600,000!

As a collaborative effort, the Working Groups from the SITC Immune Biomarkers Task Force addressed key topics in white papers focused on immune biomarker development to provide recommendations and guidance to the field.

The SITC Immune Biomarkers Task Force published a monthly primer series focused on emerging technologies for biomarker discovery as short reports in the *Journal for Immunotherapy of Cancer*.

SITC announced a collaboration with the Oncology Specialty Group and published content focused on cancer immunotherapy and society initiatives in *Targeted Therapies in Oncology, OncLive* and *Oncology Nursing News*.

SITC signed on to support the National Biomedical Research Act to create a new funding stream, the Biomedical Innovation Fund.

The SITC Immune Biomarkers Task Force, in collaboration with the Center for Cancer Research, National Cancer Institute of the National Institutes of Health, U.S. Department of Health & Human Services, organized the Immunotherapy Biomarkers 2016: Overcoming the Barriers meeting.
SOCIETY FOR IMMUNOTHERAPY OF CANCER

BOARD OF DIRECTORS

PRESIDENT (2014-2016)
Howard L. Kaufman, MD, FACS
Rutgers Cancer Institute of New Jersey

VICE PRESIDENT (2014-2016)
Lisa H. Butterfield, PhD
University of Pittsburgh

F. Stephen Hodi, Jr, MD
Dana-Farber Cancer Institute

IMMEDIATE PAST PRESIDENT (2014-2016)
(Ex-officio)
Francesco Marincola, MD
Sidra Medical and Research Center

AT-LARGE DIRECTORS
Pierre Coulie, MD, PhD (2013-2016)
De Duve Institute, Universite Catholique De Louvain

Sandra Demaria, MD (2014-2017)
New York University School of Medicine

Robert L. Ferris, MD, PhD, FACS (2014-2017)
University of Pittsburgh Cancer Institute

Jérôme Galon, PhD (2016-2019)
French National Institute of Health and Medical Research,
Cordeliers Research Center

Samir N. Khleif, MD (2016-2019)
Georgia Regents University Cancer Center

Ira Mellman, PhD (2013-2016)
Genentech

Pamela S. Ohashi, PhD (2016-2019)
Princess Margaret Cancer Centre, University Health Network

Willem W. Overwijk, PhD (2014-2017)
University of Texas, MD Anderson Cancer Center

Suzanne Topalian, MD (2013-2016)
(Ex-officio)
Johns Hopkins University

Pedro J. Romero, MD
(Ex-officio)
University of Lausanne
Editor-in-Chief, Journal for ImmunoTherapy of Cancer
Tara Withington, CAE  
Executive Director

Christopher Balderrama, MBA  
Membership Manager

Esther Berkowitz, MBChB, MA  
Director of Scientific Affairs

Betsy Foss-Campbell, MA  
Senior Program Manager

Nadine Couto, CMP  
Director of Meetings

Anna Douangphachanh  
Meetings Manager

Jody Felski  
Senior Development Manager

Kate Flynn, MPA  
Director of Strategic Partnerships

Julie Frinzi  
Director of Communications

Cari Grulke  
Meetings Coordinator

Stefanie Haasken, PhD  
Proposal Writer

Erin Irelan  
Communications Manager

Michelle Johnson  
Program Manager

Angela Kilbert  
Director of Administration

Mindon Laue, MA  
Development Coordinator

Claire Leischer, MS  
Education Manager

Kayla Lemmon  
Program Manager

Chelsey Meier, PhD  
Medical Writer

Johanna Moerke  
Project Manager

Nichole Nikolic  
Director of Membership

Andrew Palios  
Communications Manager

Brenna Ranzen  
Education Coordinator

Andrea Rindo  
Managing Editor – JITC

Michael Scorzo, EdD  
Director of Online Education

Rosie Stelpflug, MS  
Executive Assistant

Alicia Schuessler  
Director of Education Programs

Lianne Wiggins  
Program Manager

Adam Wise  
Digital Communications Manager
LET’S KEEP CANCER IMMUNOTHERAPY TOP OF MIND...